We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





COVID-19 Test Uses DNA Nanoswitch Technology to Detect SARS-CoV-2 Virus

By LabMedica International staff writers
Posted on 05 Nov 2020
An easy diagnostic test for COVID-19 based on DNA nanoswitch technology could offer a new way of detecting SARS-CoV-2, the virus causing the disease.

Scientists from the Program in Cellular and Molecular Medicine (PCMM) at Boston Children’s Hospital (Boston, MA, USA) have been developing DNA nanoswitch technology for several years, allowing them to pivot quickly to apply it to COVID-19 diagnosis. More...
The DNA nanoswitch starts with a piece of single-strand DNA. Attached to either end of that DNA are compounds that interact with molecules that a researcher wants to study - such as antibodies to a protein made by a virus. Once added to a blood serum sample, the DNA/antibody nanoswitches float along as sentries looking for their targets. Once they find them, the antibodies bind tightly. The bond between the pair of antibodies and the protein causes the DNA to change shape, shifting to a closed circle or loop shape. If no target is found, the DNA strand remains open in an unlooped position.

The nanoswitch technology developed by the PCMM scientists is not yet used clinically but has shown promise in research studies for other diseases, including detection of prostate specific antigen, a marker of prostate health. For COVID-19, the scientists are engineering a trifecta of DNA nanoswitches which can detect the spike protein of the SARS-CoV-2 virus that causes COVID-19, antibodies produced after exposure to the virus, or RNA made by the virus itself. Test results are read out by a simple gel electrophoresis system, a common analytical tool in many laboratories that sorts DNA and proteins by size and shape based on their downward movement through a gel. With a positive result - a closed loop - the sample seems to get caught and slows down, staying higher in the gel. A negative result passes through the gel to the bottom.

The scientists aim to simplify things even further for rapid, on-site COVID-19 testing by developing a test that is as easy as a pee stick, but as sophisticated and accurate as a laboratory system. The rapid test they are developing will not only detect the presence of COVID-19 antibodies, but also provide more information about those antibodies.

“Our technology, a DNA nanoswitch, is a new way of probing a test sample for evidence of infection,” said Wesley Wong, PhD, who is leading the team developing the new COVID-19 test at the PCMM. “We hope to get some insight into how the immune system responds to infection or vaccination, and maybe even identify the presence of antibodies capable of killing, or neutralizing the virus. Preliminary results on patient serum samples show the concept is promising.”

Related Links:
Boston Children’s Hospital


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.